Bergen, Norway 11 may 2023
Today Lifecare publish Q1 2023 interim report.
The consolidated group financials show a revenue in Q1 of 2.61 MNOK, compared to 1,98 MNOK in Q1 2022, while the Operating result in Q1 2023 ended at -6.38 MNOK, up from -4,88 MNOK in Q1 2022 due to increase in company's activities after reaching the clinical stage.
On the operational side the company can today disclose;
- Lifecare's first Clinical Study has been successfully finalized (https://newsweb.oslobors.no/message/590329)
- Lifecare Laboratory achieved ISO 9001 certification with effect from April 17th, 2023
- Lifecare's sensor continue to prove its robustness in combined in-vivo/in-vitro experiments
The full report is attached to this release and are also available on Lifecare's website in the Investor Section.
Lifecare AS will host an online presentation of the Q1 2023 report today at 13:00CET.
Link to the webcast:
https://teams.microsoft.com/l/meetup-join/19%3ameeting_MDY4ZWM0YmMtOGJmMS00OGRlLTg0NGItOTRjNzM1NTNhNGM1%40thread.v2/0?context=%7b%22Tid%22%3a%22c5fbb1c6-4eb0-45db-9f3c-6e20ebcd710e%22%2c%22Oid%22%3a%2271082610-7009-40ed-92e6-70ae6bc35450%22%7d
You can post questions during the event or send them in advance to: post@lifecare.no
Further information
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Joacim Holter, CEO at Lifecare AS, on 11 May 2023 at 12:36 CET.